• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    11/29/22 12:31:55 PM ET
    $AIMD
    $AKTX
    $APEN
    $AYLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email

    Gainers

    • Otonomy (NASDAQ:OTIC) shares increased by 114.7% to $0.23 during Tuesday's regular session. The current volume of 184.8 million shares is 6152.7% of Otonomy's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $13.1 million.
    • Apollo Endosurgery (NASDAQ:APEN) shares increased by 65.41% to $9.93. As of 12:30 EST, Apollo Endosurgery's stock is trading at a volume of 22.6 million, which is 21929.3% of its average full-day volume over the last 100 days. The company's market cap stands at $413.2 million.
    • OncoSec Medical (NASDAQ:ONCS) stock increased by 23.13% to $3.14. The current volume of 13.2 million shares is 4304.8% of OncoSec Medical's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $5.6 million.
    • SINTX Technologies (NASDAQ:SINT) stock increased by 15.96% to $0.13. Trading volume for this security as of 12:30 EST is 14.5 million, which is 411.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million.
    • Cosmos Holdings (NASDAQ:COSM) shares increased by 15.53% to $0.67. Trading volume for this security as of 12:30 EST is 179.0 million, which is 549.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $56.1 million.
    • Renalytix (NASDAQ:RNLX) shares increased by 15.23% to $1.74. Renalytix's stock is trading at a volume of 53.4K shares as of 12:30 EST. This is 47.0% of its average full-day volume over the last 100 days. The company's market cap stands at $65.1 million.

    Losers

    • Alaunos Therapeutics (NASDAQ:TCRT) stock fell 24.5% to $0.66 during Tuesday's regular session. The current volume of 6.4 million shares is 183.2% of Alaunos Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $142.3 million.
    • NanoVibronix (NASDAQ:NAOV) stock fell 23.53% to $0.48. The current volume of 22.7 million shares is 2782.3% of NanoVibronix's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $13.5 million.
    • Akari Therapeutics (NASDAQ:AKTX) stock declined by 17.25% to $0.48. The company's market cap stands at $28.4 million.
    • CinCor Pharma (NASDAQ:CINC) stock declined by 16.59% to $11.77. Trading volume for CinCor Pharma's stock is 1.3 million as of 12:30 EST. This is 402.8% of its average full-day volume over the last 100 days. The company's market cap stands at $515.1 million.
    • Ainos (NASDAQ:AIMD) shares declined by 13.01% to $0.6. As of 12:30 EST, this security is trading at a volume of 63.8K shares, making up 10.7% of its average full-day volume over the last 100 days. The company's market cap stands at $12.0 million.
    • Ayala Pharmaceuticals (NASDAQ:AYLA) shares decreased by 12.41% to $0.52. The company's market cap stands at $7.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $AKTX
    $APEN
    $AYLA

    CompanyDatePrice TargetRatingAnalyst
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    Apollo Endosurgery Inc.
    $APEN
    1/4/2023$10.00Buy → Hold
    Stifel
    CinCor Pharma Inc.
    $CINC
    12/7/2022$22.00Overweight
    Barclays
    Apollo Endosurgery Inc.
    $APEN
    11/30/2022$14.00 → $10.00Buy → Hold
    Lake Street
    CinCor Pharma Inc.
    $CINC
    11/29/2022Outperform → Perform
    Oppenheimer
    CinCor Pharma Inc.
    $CINC
    11/29/2022$60.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    CinCor Pharma Inc.
    $CINC
    10/28/2022$67.00Buy
    Goldman
    More analyst ratings

    $AIMD
    $AKTX
    $APEN
    $AYLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AIMD
    $AKTX
    $APEN
    $AYLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

    Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

    3/19/26 12:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

    Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, today announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market. The procedure represents SINTX's entry int

    3/19/26 7:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

    TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breastPoster Number: 3179Poster Board Number: 14Session Category: Experimental and Molecular TherapeuticsSession Title: Targeting Cell Surface Vulne

    3/18/26 8:05:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AKTX
    $APEN
    $AYLA
    SEC Filings

    View All

    Akari Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Akari Therapeutics Plc (0001541157) (Filer)

    3/17/26 5:07:26 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Akari Therapeutics plc

    SCHEDULE 13G/A - Akari Therapeutics Plc (0001541157) (Subject)

    3/4/26 4:44:32 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Akari Therapeutics Plc (0001541157) (Filer)

    3/2/26 5:00:26 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AKTX
    $APEN
    $AYLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SiNtx Technologies Inc.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/18/26 9:02:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Neal James R

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    3/16/26 5:00:03 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AIMD
    $AKTX
    $APEN
    $AYLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Akari Therapeutics with a new price target

    Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00

    7/18/25 9:02:34 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollo Endosurgery downgraded by Stifel with a new price target

    Stifel downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00

    1/4/23 7:13:09 AM ET
    $APEN
    Industrial Specialties
    Health Care

    $AIMD
    $AKTX
    $APEN
    $AYLA
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

    Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

    3/19/26 12:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AIMD
    $AKTX
    $APEN
    $AYLA
    Financials

    Live finance-specific insights

    View All

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AIMD
    $AKTX
    $APEN
    $AYLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care